Clinical Trials

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

A major investment in natural killer cell immunotherapy aims to revolutionize treatment for Canada's most fatal women's cancer after decades of stagnation.

A new gene therapy has helped completely blind patients with Retinitis Pigmentosa regain light perception, offering hope to millions with inherited blindness.

A new collaboration leverages a vast cord blood bank and advanced AI to create off-the-shelf cell therapies, promising a new era in regenerative medicine.

Anika Therapeutics posts strong Q1 results with a 13% revenue jump, but analyst caution lingers over pipeline risks and long-term sustainability.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

A new therapy programs immune cells inside the body to fight disease. Sail Biomedicines is pioneering this approach to offer a potential cure for autoimmunity.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

New guidelines advise biennial screening for women 50-74 and caution for others, a move that has drawn sharp criticism from other medical bodies.